Read one source in full context
Mechanism and measured outcomes.
Read each source with its population and outcome attached. The mechanism field describes the scientific background; the measured-outcome field states what a trial found or a label authorizes. The boundary explains which further conclusions that record cannot establish.
These fixed summaries explain public evidence. They do not assess your health, choose a medicine or provide a treatment plan. Approved-product outcomes, exact compounded preparations and marketed microdosing programs are different evidence questions. Absence of verified evidence for a particular promise is not proof that no effect is possible.
Approved-product labeling, revised August 2026
Tirzepatide in current product labels
Mechanism
The Zepbound and Mounjaro labels describe tirzepatide as activating GIP and GLP-1 receptors. These targets help explain effects on appetite and glucose regulation. Some details in the mechanism discussion come from nonclinical research; identifying two receptor targets does not itself measure a person’s future health.
Measured outcome
A label summarizes authorized uses and supporting evidence; it is not a new trial. Zepbound has defined weight-management uses and an indication for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro’s current label includes reducing major cardiovascular events in adults with type 2 diabetes at high risk, as well as glycemic-control uses. Human outcome evidence therefore exists for specified approved products and populations.
Where the finding applies
Those indications do not establish that CoreAge’s advertised compounded microdosing preparation extends life or reproduces the approved products’ results. FDA does not review compounded drugs for safety, effectiveness and quality before marketing. The supplied medicine, proposed purpose and supporting evidence still need to be distinguished.
Two randomized clinical trials, published 2024
SURMOUNT-OSA: breathing during sleep
Mechanism
Tirzepatide’s effects on appetite and body weight are relevant background to these trials. FDA described the sleep-apnea improvement as likely related to weight reduction. That explanation does not prove that an isolated GIP pathway independently treated the condition.
Measured outcome
Two trials enrolled 469 adults with obesity and moderate-to-severe obstructive sleep apnea, without type 2 diabetes. One group of participants used positive airway pressure at baseline; the other did not. The primary measure was change in apnea-hypopnea index, which counts breathing interruptions per hour of sleep. At 52 weeks, the trial treatments produced larger reductions than placebo.
Where the finding applies
These were defined clinical protocols, not a trial of a branded compounded microdosing service. The researchers did not establish whether patients could stop positive airway pressure, and the trials were not designed to assess long-term cardiovascular outcomes. Existing sleep-apnea treatment decisions belong with the treating team. Later approved uses of tirzepatide do not change what these particular trials measured.
Extended randomized-trial analysis, first published 2024
SURMOUNT-1 follow-up: progression to diabetes
Mechanism
Receptor activity and changes in weight or glucose-related markers can suggest possible pathways. A clinical endpoint asks a separate question. This analysis measured the development of type 2 diabetes rather than treating a laboratory improvement alone as proof of disease prevention.
Measured outcome
The report focused on 1,032 participants who had prediabetes and obesity or qualifying overweight at the start of SURMOUNT-1. Overweight eligibility required an obesity-related complication. By 176 weeks, type 2 diabetes had developed in 1.3% of participants across the pooled tirzepatide groups and 13.3% of the placebo group. These are results within a specified population and follow-up period, not an estimate for every person considering treatment.
Where the finding applies
The study did not measure added years of life in healthy adults or test CoreAge’s particular compounded microdosing program. A lower observed frequency of diabetes during a trial does not establish permanent protection. FDA’s distinction between biomarkers and clinical outcomes helps explain why neither a favorable marker nor a disease-specific result settles a broad longevity promise.
Randomized open-label trial, published 2025
SURMOUNT-5: a defined comparison of weight outcomes
Mechanism
Tirzepatide and semaglutide have different receptor activity. SURMOUNT-5 compared actual injectable trial treatments, rather than awarding an advantage from receptor count alone. The study does not isolate how much of any difference came from one receptor pathway.
Measured outcome
The trial randomized 751 adults with obesity or qualifying overweight, without type 2 diabetes. Overweight eligibility required a prespecified obesity-related complication. The primary endpoint was percentage weight change at 72 weeks. The primary analysis reported average reductions of 20.2% with tirzepatide and 13.7% with semaglutide. Treatment assignment was known, and Eli Lilly funded the trial.
Where the finding applies
The result supports a specific comparative weight finding under the trial’s conditions. It does not rank commercial microdosing programs, establish a universal safety winner or measure healthy-person longevity. Neither different later product presentations nor an unspecified compounded preparation can simply inherit the finding. This record supplies no conversion or treatment-switch instructions.